EOLS Research | Milton Maxwell

EOLS

Evolus, Inc.

7.22

+0.08+1.12%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q4 '25

3/3/26Mar 3, 2026

Key Stats

Market Cap

468.00M

P/E (TTM)

Basic EPS (TTM)

-0.90

Dividend Yield

Recent Filings

8-K

3/13/26Mar 13, 2026

10-K

3/3/26Mar 3, 2026

8-K

3/3/26Mar 3, 2026

8-K

1/9/26Jan 9, 2026

10-Q

Q3 FY2025 results

11/5/25Nov 5, 2025

Evolus posted Q3 revenue of $69M, up 12.9% y/y from $61M, fueled by Jeuveau at $63M (up 5.1% y/y) and new Evolysse launch adding $5.7M; gross margin slipped to 66.5% from 68.9% on higher volume. Operating loss narrowed to $11.5M from $15.5M y/y while net loss improved to $15.7M from $19.2M, with the gap to operating loss driven by $4.1M interest expense. Cash burned $55M YTD on inventory builds versus $23M last year; $43.5M remains on hand against $146M term debt (SOFR+5%, due 2030). Revenue growth persists. Jeuveau faces BOTOX dominance.

About

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

CEO

Mr. David Moatazedi

IPO

2/8/2018

Website

https://www.evolus.com

Employees

329

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic